Friday, 18 Aug 2017

You are here

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on 

  1. FDA accepts Pfizers NDA for Xeljanz (tofacitinib) as treatment for moderately to severely active ulcerative colitis
  2. FDA rejects Romosuzumab (anti-Sclerostin OP Rx) w/ a complete response letter asking for resubmission, more data
  3. RA ACPA+ have higher economic burden with MORE early DMARD use (71 vs 50%) & Biologic use (20 vs 12%); more MD visits; & more Total costs
  4. Mucosal immunity seen in at-risk RA (preclinical) people who had more IgA producing plasmablasts (39%) than established RA or normal controls(1%, 9%) 
  5. 7 patients with Active Refractory Takayasu arteritis treated with RTX showed mixed results - 3 achieved remission but 4 failed to respond to RTX.  
  6. Study of 38,924 shows dairy intake assoc with an increased risk of OA hip replacement (unrelated to age, BMI, smoking, activity
  7. 1979-2013 Septic arthritis in RA has increased and associated with more biologic use, polyarticular infections, MRSA (6% v 31%); but same outcomes
  8. Alcohol & Smoking assoc w/ 2 fold risk of Hand OA. but being overweight or obese is NOT.
  9. MTX has yet to be shown to benefit Osteoarthritis; but there is a new PROMOTE trial looking at pain reduction. Still enrolling.
  10. Zurampic 200mg + Uloric fails vs Uloric alone at achieving two primary endpoints SUA<5 (57% vs 47%) & topus resolution (no diff btw groups).
  11. Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too 
  12. Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis 
  13. Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus 
  14. FDA Approves Tremfya (guselkumab) for Plaque Psoriasis


Rheumatologists' Comments

Decades ago waited 12 weeks to diagnose RA. Now can think pre RA Great! Anticipating more in shorter time frame.

More Like This

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from This week's report includes new data on lupus survival, pediatric lupus guidelines from SHARE, room temperature storage of etanercept, over or under-testing by rheumatologists and failure of pain meds to treat pain.

The RheumNow Week in Review – 11 August 2017

The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.  This week's news highlights include new data on the incidence of arthritis, lag times in patient referral, criteria for referral and why/how weather change affects arthritis pain.

Criteria for Early Referrals from Primary Care

Early diagnosis and early intervention has been the mantra of all who manage musculoskeletal (MSK) diseases for decades. While the rules for referral may be clear to some, the lack of uniformity and promotion amongst primary care providers is less certain.

MSK Ultrasound Now Standard for Rheumatology Training

In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on